Defunct Company
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
102
NCT02506933
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
Phase: Phase 2
Role: Collaborator
Start: Nov 5, 2015
Completion: Jun 9, 2026